Mooradian, M., Karunamurthy, A., Wang, H., Buchbinder, E. I., Rapisuwon, S., Cohen, J. V., Gibney, G. T., Sullivan, R. J., Luke, J. J., Najjar, Y. G., Kirkwood, J. M., Zarour, H. M., Davar, D. (2025). Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba9504